SCHEMBL6889978

SCHEMBL6889978

CCc1c(Cl)cccc1[N+](=O)[O-]

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
KDM4E B2RXH2 2/20 0.51
LMNA P02545 1/20 0.51
TDP1 Q9NUW8 3/20 0.48
CYP1A2 P05177 2/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
GAA P10253 1/20 0.48
HPGD P15428 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
FBP1 P09467 1/20 0.46
MAPT P10636 3/20 0.45
MAPK1 P28482 2/20 0.45
POLB P06746 1/20 0.45
TSHR P16473 3/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GPR35 Q9HC97 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8361517 0.86 TDP1 (0.58) ALDH1A1LMNATDP1GAAMEN1
SCHEMBL7784647 0.84 ALDH1A1 (0.54) ALDH1A1KDM4ELMNATDP1CYP1A2
SCHEMBL29975243 0.83 ALDH1A1 (0.53) ALDH1A1KDM4ELMNATDP1CYP1A2
SCHEMBL10756135 0.83 ALDH1A1 (0.53) ALDH1A1KDM4ELMNATDP1CYP1A2
SCHEMBL18185045 0.82 LMNA (0.46) ALDH1A1KDM4ELMNATDP1CYP1A2
SCHEMBL4715285 0.81 ALDH1A1 (0.55) ALDH1A1KDM4ELMNATDP1CYP1A2
SCHEMBL31148323 0.81 ALDH1A1 (0.51) ALDH1A1KDM4ELMNATDP1CYP1A2
SCHEMBL4146683 0.81 ALDH1A1 (0.51) ALDH1A1KDM4ELMNATDP1CYP1A2
SCHEMBL844236 0.81 ALDH1A1 (0.51) ALDH1A1KDM4ELMNATDP1CYP1A2
SCHEMBL5681342 0.81 ALDH1A1 (0.51) ALDH1A1KDM4ELMNATDP1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257380-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE CULLGEN (SHANGHAI), INC. (CN) 2023-08-17 US disclosed
EP-3008045-B1 ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS ANTABIO SAS (FR) 2018-05-09 EP disclosed
US-9914712-B2 Antibacterial thiazolecarboxylic acids ANTABIO SAS (FR) 2018-03-13 US disclosed
CN-107311921-A Aryl or heteroaryl-substituted compound EPIZYME股份有限公司 2017-11-03 CN disclosed
CN-104066718-B Substituted benzene compounds EPIZYME股份有限公司 2017-08-29 CN disclosed
CN-104080769-B Aryl or heteroaryl substituted benzene compounds EPIZYME股份有限公司 2017-06-20 CN disclosed
US-20170015631-A1 PKM2 MODULATORS AND METHODS FOR THEIR USE SUMITOMO PHARMA ONCOLOGY, INC. 2017-01-19 US disclosed
US-20160272601-A1 Antibacterial Thiazolecarboxylic Acids ANTABIO SAS (FR) 2016-09-22 US disclosed
US-9062042-B2 Nicotinic acetylcholine receptor modulators ASTRAEA THERAPEUTICS, LLC (US) 2015-06-23 US disclosed
US-20110172264-A1 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS ASTRAEA THERAPEUTICS, LLC 2011-07-14 US disclosed
US-7279484-B2 Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease AJINOMOTO CO., INC. (JP) 2007-10-09 US disclosed
US-7271270-B2 High affinity small molecule C5a receptor modulators NEUROGEN CORPORATION (US) 2007-09-18 US disclosed
EP-0325892-B1 PROCESS FOR THE PREPARATION OF HALOGENATED PRIMARY AMINES CIBA-GEIGY AG (CH) 1993-02-03 EP disclosed
EP-0473552-A1 Process for the preparation of halogenated aromatic primary amines CIBA-GEIGY AG (CH) 1992-03-04 EP disclosed
US-5064746-A RADIATION-SENSITIVE MIXTURE FOR PHOTOSENSITIVE COATING MATERIALS AND THE PRODUCTION OF RELIEF PATTERNS AND RELIEF IMAGES BASF AKTIENGESELLSCHAFT (DE) 1991-11-12 US disclosed
US-4960936-A Process for the preparation of halogenated aromatic primary amines CIBA-GEIGY CORPORATION (US) 1990-10-02 US disclosed
EP-0325892-A2 Process for the preparation of halogenated primary amines CIBA-GEIGY AG (CH) 1989-08-02 EP disclosed
US-4812542-A PHOTORESISTS, LIGHT-SENSITIVE COATINGS BASF AKTIENGESELLSCHAFT (DE) 1989-03-14 US disclosed
US-4808682-A BLEND WITH OLEFINICALLY UNSATURATED SILICON COMPOUND BASF AKTIENGESELLSCHAFT (DE) 1989-02-28 US disclosed
US-3989756-A RANEY CATALYST, DEHALOGENATION INHIBITOR NIPPON KAYAKU KABUSHIKI KAISHA (JA) 1976-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257380-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE MUSK, ERBB2, NTRK1 ALDH1A1 4113/4885KDM4E 3125/4885LMNA 1083/4885
US-20110172264-A1 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS CHRNA4, CHRNA3, CHRNA6 ALDH1A1 788/4885KDM4E 718/4885LMNA 4186/4885
US-20160272601-A1 Antibacterial Thiazolecarboxylic Acids ME1, TALDO1, COASY ALDH1A1 40/4885KDM4E 3604/4885LMNA 1543/4885
US-20170015631-A1 PKM2 MODULATORS AND METHODS FOR THEIR USE PDK1, PDK2, PKM ALDH1A1 2333/4885KDM4E 297/4885LMNA 1822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.